Purpose: To investigate the potential effects of systemic fingolimod treatment on parameters of the anterior segment of the eye and tear film function tests in patients with multiple sclerosis (MS).
Methods: Forty-eight eyes of 24 individuals who were started on systemic fingolimod treatment for relapsing-remitting MS were prospectively enrolled in this study. Patients underwent examinations immediately before initiation of systemic fingolimod treatment, and at the first and sixth months of treatment. Anterior segment parameters were measured using Sirius Topography. The Schirmer-I test and tear break-up time (TBUT) were recorded during follow-up. Retinal thickness was also analyzed using spectral-domain optical coherence tomography (SD-OCT).
Results: There was no statistically significant difference in retinal thickness measurements between follow-up visits. The central corneal thickness, keratometric values, anterior chamber depth, aqueous humor depth, iridocorneal angle, horizontal anterior chamber tilt and anterior chamber volume values remained similar during follow-up. The Schirmer-I test value was 15.10 ± 2.65 mm at the zeroth month and 17.03 ± 3.61 mm at the sixth month ( = 0.044). The mean TBUT was significantly higher at the six-month visit compared to baseline and the one-month visit ( < 0.001, < 0.001), but there was no statistically significant difference between baseline and month 1 ( = 0.419).
Conclusion: Systemic use of fingolimod may increase Schirmer I test and TBUT values in MS patients without altering other anterior segment parameters within 6 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15569527.2024.2432508 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of systemic fingolimod treatment on anterior segment parameters and tear film functions.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkey.
Purpose: To investigate the potential effects of systemic fingolimod treatment on parameters of the anterior segment of the eye and tear film function tests in patients with multiple sclerosis (MS).
Methods: Forty-eight eyes of 24 individuals who were started on systemic fingolimod treatment for relapsing-remitting MS were prospectively enrolled in this study. Patients underwent examinations immediately before initiation of systemic fingolimod treatment, and at the first and sixth months of treatment.
Behavioral Analyses in Dark Agouti Rats Following Repeated Systemic Treatment With Fingolimod (FTY720).
Brain Behav
November 2024
Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Background: Studies in experimental animals revealed that acute and chronic treatment with small-molecule immunosuppressive drugs lead to neurobehavioral alterations in rodents.
Methods: Against this background, this study investigated behavioral alterations in rats after repeated administration of FTY720, an immunosuppressive drug used for the treatment of multiple sclerosis, employing the open field, elevated plus maze, and dark/light tests.
Results: Compared to controls, repeated FTY720 treatment affected behavior in rats, reflected by a reduction in distance traveled as well as increased time engaged in freezing in the open field and elevated plus maze.
Concurrent Primary Cutaneous Cryptococcosis and Bowen's Disease in a Patient With Multiple Sclerosis on Fingolimod: A Rare Case Report and Review of Literature.
Cureus
October 2024
Department of Dermatology, Bezmialem Vakif University Faculty of Medicine, Istanbul, TUR.
Fingolimod is an oral disease-modifying treatment used for the relapsing-remitting forms of multiple sclerosis, which may render patients susceptible to opportunistic infections and lead to an increased risk of skin cancer. We report a 56-year-old woman with multiple sclerosis in remission on fingolimod treatment for five years presenting with the following skin lesions. Our patient presented with a non-healing ulcerated erythematous lesion on the left lower abdomen for six months and a crusted erythematous plaque on the forehead that had not healed for one year.
View Article and Find Full Text PDFDiagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update.
Paediatr Drugs
July 2024
Department of Pediatric Rheumatology, Hacettepe University Medical Faculty, Sihhiye Campus, 06100, Ankara, Turkey.
Article Synopsis
- * While MRI is useful for detecting major neurological issues, it often lacks the resolution to identify smaller problems, necessitating the use of advanced imaging techniques like PET or SPECT.
- * Treatment mainly focuses on relieving symptoms and addressing the underlying disease, with strong immunosuppressants like cyclophosphamide and rituximab being recommended, along with ongoing research into new biologic therapies.
Platelet Function is Independent of Sphingolipid Manipulation.
J Surg Res
August 2024
Department of Surgery, University of Cincinnati, Cincinnati, Ohio. Electronic address:
Introduction: Previous literature suggests that sphingolipids may impact systemic coagulation and platelet aggregation, thus modulating the risks of thrombotic events. The goal of this investigation was to evaluate the role of serum sphingolipids on intrinsic platelet function to assess whether pharmacologic manipulation of sphingolipid metabolites would impact platelet aggregability.
Methods: C57BL/6J mice were injected with either normal saline, 1 mg/kg FTY720 (synthetic sphingosine-1-phosphate [S1P] receptor analog), or 5 mg/kg SLM6031434 (sphingosine kinase two inhibitor).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!